The California attorney general has filed a lawsuit accusing several drugmakers and pharmacy benefit managers of conspiring to set prices for insulin, joining a growing list of states that have taken such a step as more and more Americans struggle to afford the life-savings diabetes treatment.
The lawsuit alleges that the companies “unconscionably, deceptively, misleadingly, and artificially” drove up the cost of insulin, making the medication unaffordable for many of the 3 million state residents with diabetes and causing the state government to overpay for the medication. The lawsuit also maintained the pricing disproportionately harms low-income communities.
Specifically, the state charged that the manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — worked in “lockstep” to “artificially” raise prices even as production costs plummeted. And the state also alleged the largest pharmacy benefit managers in the U.S. — Express Scripts, CVS Caremark and OptumRx — profited by receiving “secret” rebates from the manufacturers.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect